Opus Genetics, Inc. (IRD)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 14,196,000 29.1%
- Net income
- -49,591,000
- Operating income
- -38,599,000
- Earnings per share
- -0.80
Growth and profitability
- Operating margin
- -271.90
- Net margin
- -349.33
- Return on equity
- -323.11
- Return on assets
- -98.70
Balance sheet
- Total assets
- 50,243,000
- Total liabilities
- 34,895,000
- Shareholders' equity
- 15,348,000
- Cash and equivalents
- 45,091,000
- Debt
- 1,129,000
- Net debt
- -43,962,000
- Current ratio
- 6.43
- Debt to equity
- 0.07
Cash flow and ratios
- Operating cash flow
- -35,253,000
Shareholder returns
- Shares outstanding
- 96,654,336
- Book value per share
- 0.16
Company information
- Headquarters
- Durham, NC
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Opus Genetics, Inc. trades on NASDAQ under the ticker symbol IRD. This page brings together its price chart, company profile, key financial figures and technical indicators.